Blood-brain barrier (BBB) dysfunction has been found in multiple neurodegenerative conditions, including mild cognitive impairment (MCI) and Alzheimer’s disease (AD). However recent concerns on the repeated use of Gadolinium based contrast agents (GBCAs), prompted us to investigate alternative, non-invasive methods for measuring BBB function. Both diffusion-weighted (DW) and multi-echo (ME) ASL was implemented at 3T to determine water transfer rates (kw) in the brain in MCI and early AD participants. We found kw to be lower in the cognitively impaired group, compared to controls, with both modalities, suggesting that these techniques may provide a marker of early AD pathology.
This abstract and the presentation materials are available to members only; a login is required.